1. 2016 ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More

2. Introduction

3. Principles of AF Management

4. 2016 ESC Guidelines for Diagnosis and Management of AF: Key Recommendations

5. 2016 ESC Guidelines for Diagnosis and Management of AF: Key Recommendations (cont)

6. 2016 ESC Guidelines for Diagnosis and Management of AF: Key Recommendations (cont)

7. 2016 ESC Guidelines for Diagnosis and Management of AF: Key Recommendations (cont)

8. Real-World Data: An Important Source of Evidence

9. Real-World Data: NOACs

10. Drug Adherence and Persistence Results

11. Real-World Data: NOACS (cont)

12. Risk of Bleeding Among Elderly Patients on NOACs

13. Real-World Data: NOACs (cont)

14. Persistence of NOACs by Cohort Among NOAC-Naive Patients

15. Real-World Data: NOACs (cont)

16. Propensity Score-Matched Adjusted Incidence Rates of Major Bleeding
Propensity Score-Matched Adjusted Incidence Rates of Major Bleeding* and HRs for Anticoagulant Initiation

17. Real-World Data: NOACs (cont)

18. Real-World Data: NOACs (cont)

19. ENSURE-AF: Edoxaban for Cardioversion of AF

20. Ensure-AF: Primary Efficacy Endpoint Results

21. Stroke Prevention in AF: Some Important Considerations

22. Things to Consider When Starting/Choosing a NOAC . . . Think ABCDE

23. Summary and Conclusions

24. Abbreviations

25. Abbreviations